Dongfang Wu

发表

Treatment beyond progression with chemo-immunotherapy in an advanced esophageal squamous cell carcinoma patient: a case report

Chao Sun, P. Peng, Yajie Xiao, 2021, Translational cancer research.

BUB1 Is Identified as a Potential Therapeutic Target for Pancreatic Cancer Treatment

Yajie Xiao, Zhikun Zhao, Dongfang Wu, 2022, Frontiers in Public Health.

Exploring the Interplay between Metabolism and Tumor Microenvironment Based on Four Major Metabolism Pathways in Colon Adenocarcinoma

Guangmei Zhang, Yajie Xiao, Zhikun Zhao, 2022, Journal of oncology.

Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases

Jie Yang, F. Kong, Dongfang Wu, 2022, Frontiers in Oncology.

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report

Y. Guan, Dongfang Wu, Junjuan Xiao, 2022, Frontiers in Oncology.

In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.

Jun Liu, Yajie Xiao, Zhikun Zhao, 2021, Journal of Clinical Oncology.

Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer

Wei Wang, Weiqi Wang, Hanqing Lin, 2022, Journal of oncology.

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple‐negative breast cancer

Haitao Luo, Yanhui Zhu, Xiaoan Liu, 2022, Cancer medicine.

Comprehensive Analysis of Histone Modifications in Hepatocellular Carcinoma Reveals Different Subtypes and Key Prognostic Models

H. Mu, Yajie Xiao, Zhikun Zhao, 2022, Journal of oncology.

Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making

Daqiang Sun, Mei-lin Xu, Dongfang Wu, 2022, Frontiers in Oncology.

The mechanism of lncRNAs in the crosstalk between epithelial-mesenchymal transition and tumor microenvironment for early colon adenocarcinoma based on molecular subtyping

Yajie Xiao, Zhikun Zhao, Dongfang Wu, 2022, Frontiers in Genetics.

Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report

Chao Sun, Liping Zhang, Yuwei Cao, 2021, Frontiers in Oncology.

Systematic analysis of molecular characterization and clinical relevance of m6A regulators in digestive system pan-cancers

Zhongtao Zhang, Z. Bai, Ruizhi Chai, 2021, Experimental biology and medicine.

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma

Dongfang Wu, Wei Wang, Xue-jia Lin, 2023, Frontiers in Oncology.

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients

Yajie Xiao, Zhikun Zhao, Dongfang Wu, 2022, Cancer cell international.

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series

Yuan-hong Gao, Rong Zhang, Hanqing Lin, 2021, Frontiers in Immunology.

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model

Jiaqian Wang, Zhibo Gao, N. Li, 2022, Frontiers in Immunology.

Correlation between Tumor Microenvironment and Immune Subtypes Based on CD8 T Cells Enhancing Personalized Therapy of Gastric Cancer

Hai-feng Yang, Yajie Xiao, Dongfang Wu, 2022, Journal of oncology.

The Identification of Two RNA Modification Patterns and Tumor Microenvironment Infiltration Characterization of Lung Adenocarcinoma

Yang-li Liu, Hui Li, Geng-peng Lin, 2022, Frontiers in Genetics.

Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial

Zhigang Song, Jing Zhang, S. Jiao, 2023, EBioMedicine.

Identification and Validation of 7-lncRNA Signature of Epigenetic Disorders by Comprehensive Epigenetic Analysis

Yu Deng, Peng Cao, Yajie Xiao, 2022, Disease markers.

Abstract CT544: Multi-omics analysis uncovers prognostic biomarkers and tumor ecosystem dynamics during toripalimab combined with nab-paclitaxel and s-1 as neoadjuvant therapy for esophageal squamous carcinoma: A single-center, open-label, single-arm phase 2 trial

Haitao Luo, Jing Yuan, Zhigang Song, 2022, Cancer Research.

Molecular characteristics of multiple primary pulmonary nodules under a three-dimensional reconstruction model and relevant multi-omics analyses: a case report

Yajie Xiao, Zhikun Zhao, Dongfang Wu, 2023, Frontiers in Oncology.

Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment

Chao Sun, Yajie Xiao, Zhikun Zhao, 2022, Frontiers in Immunology.

Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations

Zhikun Zhao, Dongfang Wu, Qiu-ying Jiang, 2022, BMC Cancer.

Understanding the Critical Role of Glycolysis-Related lncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes

Yu Deng, Peng Cao, Yajie Xiao, 2022, BioMed research international.

Genomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma

Yajie Xiao, Zhikun Zhao, Dongfang Wu, 2022, Journal of oncology.

Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations

Zhikun Zhao, Dongfang Wu, Qiuyi Jiang, 2022, BMC cancer.

A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.

Qianwen Li, Yajie Xiao, Dongfang Wu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.